IV infusion of casirivimab and imdevimab authorized for treatment of mild-to-moderate COVID-19
FDA Issues EUA to Baricitinib Plus Remdesivir for COVID-19
Emergency use authorization applies to hospitalized patients requiring supplemental oxygen, mechanical ventilation, ECMO
Fluvoxamine Linked to Reduction in Clinical Deterioration in COVID-19
Findings seen among adult outpatients with SARS-CoV-2 with oxygen saturation of 92 percent or greater
Nebulized Interferon Beta-1a Promising for COVID-19
Adults hospitalized for COVID-19 receiving SNG001 versus placebo more likely to show clinical improvement
Tocilizumab Does Not Prevent Intubation, Death in COVID-19
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients
NIH Launches Trial of Antibody Drugs Against COVID-19
The phase 2 trial will assess effectiveness of monoclonal antibodies in conjunction with remdesivir
COVID-19 Antibody Treatment Study Paused
ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused ‘out of an abundance of caution’
Remdesivir Cuts Time to COVID-19 Recovery
However, no significant difference in mortality found between remdesivir and placebo groups